Theralase Technologies (CVE:TLT) Stock Price Down 13.5% – Here’s What Happened

Theralase Technologies Inc. (CVE:TLT) shares were down 13.5% on Monday . The stock traded as low as C$0.15 and last traded at C$0.16. Approximately 1,487,130 shares traded hands during mid-day trading, an increase of 1,324% from the average daily volume of 104,459 shares. The stock had previously closed at C$0.19.

Theralase Technologies Stock Up 3.2%

The stock has a fifty day moving average of C$0.19 and a two-hundred day moving average of C$0.20. The company has a quick ratio of 3.40, a current ratio of 1.91 and a debt-to-equity ratio of 14.85. The stock has a market cap of C$41.13 million, a price-to-earnings ratio of -8.89 and a beta of -0.22.

About Theralase Technologies

Theralase Technologies Inc, a clinical stage pharmaceutical company, engages in the research and development of light activated photo dynamic compounds (PDCs) and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally. It also designs, develops, manufactures, and markets patented and proprietary super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions.